April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Multiple Endpoint Analysis of BAK-Preserved and Unpreserved Antiallergic Eye Drops on the 3D-Reconstituted Corneal Epithelial Model (SkinethicTM)
Author Affiliations & Notes
  • A. Pauly
    Therapeutic Department - Equipe 8-, Inserm UMR S 968 - Institut de la Vision, Paris, France
    Dept of Toxicology, Faculty of biological and pharmaceutical Sciences - Paris-Descartes University, Paris, France
  • F. Brignole-Baudouin
    Therapeutic Department - Equipe 8-, Inserm UMR S 968 - Institut de la Vision, Paris, France
    Dept of Toxicology, Faculty of biological and pharmaceutical Sciences - Paris-Descartes University, Paris, France
  • C. Baudouin
    Ophthalmology, Quinze-Vingts Hospital, Paris, France
  • Footnotes
    Commercial Relationships  A. Pauly, LaboratoiresTHEA, 12 rue Louis Blériot, 63017 Clermont-Ferrand, FRANCE, F; F. Brignole-Baudouin, None; C. Baudouin, Laboratoires THEA, 12 rue Louis Blériot, 63017 Clermont-Ferrand, FRANCE, C.
  • Footnotes
    Support  Laboratoires THEA Grant
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 1944. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Pauly, F. Brignole-Baudouin, C. Baudouin; Multiple Endpoint Analysis of BAK-Preserved and Unpreserved Antiallergic Eye Drops on the 3D-Reconstituted Corneal Epithelial Model (SkinethicTM). Invest. Ophthalmol. Vis. Sci. 2010;51(13):1944.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the effects of benzalkonium chloride (BAK)-preserved and unpreserved antiallergic eye drops on the human 3D reconstituted corneal epithelial model (HCE).

Methods: : The HCE were treated for 24h followed or not by a 24-h post-incubation recovery period with phosphate-buffered saline (PBS), 0.01% BAK, unpreserved ketotifen formulation, unpreserved NAAGA commercial solution, and BAK-preserved commercial formulations of ketotifen and epinastine. The cellular viability was evaluated using the MTT test at 24h and 24h+24h. At 24h, the number of CD54- and Ki67- immunopositive cells as well as the number of apoptotic TUNEL-positive cells was evaluated on frozen sections. The expression of tight-junction associated proteins occludin was also assessed using fluorescence confocal microscopy on flat-mounted epithelia.

Results: : The MTT and the TUNEL tests revealed a significant decrease of cell viability and an increased apoptosis in the superficial layers of the HCE treated with the BAK-containing formulations only. The expression of CD54, Ki67 in the basal layers was also increased in this group. A dose-dependent disorganization of occludin distribution in the epithelium treated with BAK- containing solutions was also observed. Unpreserved solutions induced effects comparable to the control.

Conclusions: : BAK-preserved solutions decreased cell viability and induced apoptosis. Moreover, they induced CD54 expression, proliferation in the basal layers, and changes in the distribution of occludin, which is consistent with a disorganization of the tight-junctions and suggests the loss of the epithelial barrier function.

Keywords: cornea: epithelium • ocular irritancy/toxicity testing • apoptosis/cell death 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×